EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

This is a Phase I/II, open-label, first-in human study of GRWD5769 alone, and in combination with another anti-cancer agent in advanced solid cancers.

Trial Details

NCT ID

NCT06923761

Phase

PHASE1 / PHASE2

Sponsor

Grey Wolf Therapeutics

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

Module 1 (GRWD5769 on its own as monotherapy)
Module 2 (GRWD5769 in combination with cemiplimab, administered IV)

Locations (sample)

Adelaide, Australia|-34.92866,138.59863
Bedford Park, Australia|-35.02204,138.56815
Blacktown, Australia|-33.76667,150.91667
Darlinghurst, Australia|-33.87939,151.21925
Heidelberg, Australia|-37.75,145.06667

Key Eligibility Criteria

Provision of written informed consent.
Male or female, ≥ 18 years of age.
An ECOG performance status of 0 or 1.
Willing to permit access to stored historical tumour tissue and prior tumour radiological assessments and tumour biomarker data (if available).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →